22 February 2024
22 February 2024
Cabenuva demonstrated efficacy against daily oral ART in the Phase III trial.
In the study investigating Pelvital’s Flyte device, 71% of participants achieved continence in two to 12 weeks.
The Canadian company is looking for partners to conduct global clinical trials of its liquid device that prevents or reduce adhesions following surgeries.
The primary focus of the Phase II trial is to evaluate the safety of RLS-0071.
The trial will assess the tolerability, safety, pharmacokinetic and pharmacodynamic effects of the ALETA-001 monotherapy.
Nearly 24% patients responded to 2-OHOA while a patient had exceptional response maintained for over three years.
PrimeC demonstrated a statistically significant slowing of disease progression compared to the placebo.
The upcoming Clinical Trial Supply New England 2024 conference will gather pharma and biotech colleagues to discuss what’s to come for the clinical trial supply industry.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
